Transforming NSCLC Care: Innovation, Differentiation, and Market Opportunity
The NSCLC treatment landscape is rapidly evolving, driven by the expansion of immunotherapies and targeted therapies into earlier lines of treatment. With diagnosed incident cases projected to rise by 22% across the US, EU5, and Japan by 2042, the market is forecast to grow from $26.2B in 2024 to $49.3B by 2033.
PD-1/PD-L1 inhibitors remain the dominant drug class, with Keytruda leading the first-line setting. However, biosimilar erosion post-2028 is expected to shift market dynamics. Meanwhile, EGFR-targeted therapies—especially Tagrisso and Rybrevant—are reshaping the treatment paradigm for mutation-positive patients. The KRAS G12C segment is also emerging as a key commercial opportunity, with Lumakras and Krazati poised for growth.
The market is further diversified by the rise of novel targets such as HER2, MET, RET, and NTRK, and the anticipated launch of 34 pipeline therapies across 12 drug classes. Despite the complexity of the biomarker landscape, first-to-market advantage and label expansions remain critical for commercial success.
In this report we cover:
- Key growth drivers: PD-1/PD-L1 inhibitors, EGFR and KRAS-targeted therapies, and rising incident cases in the US, EU5, and Japan.
- Promising therapies: Tagrisso, Rybrevant, Keytruda, and Krazati.
- Novel modalities: Bispecific antibodies, antibody-drug conjugates (ADCs), and next-gen checkpoint inhibitors.
